Loading
VT3989 is an experimental pill from Vivace Therapeutics, in phase 2 trials for mesothelioma.
VT3989 is a small molecule, oral from Vivace Therapeutics. Stops TEAD transcription factors in the Hippo pathway from attaching a fatty acid to themselves (autopalmitoylation), which they need to drive cancer cell growth. Its phase 1/2 study (NCT04665206) is recruiting people with solid tumours, mesothelioma and non-small cell lung cancer; a phase 3 study in pleural mesothelioma (NCT07824986) is registered and not yet recruiting. TEAD has no target record in OnCo.
Stops TEAD transcription factors in the Hippo pathway from attaching a fatty acid to themselves (autopalmitoylation), which they need to drive cancer cell growth.
1.VT3989 slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"VT3989" OR ABSTRACT:"VT3989") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about VT3989, not a curated reading list.
Shares Pleural mesothelioma, Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Shares Mesothelioma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/